Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: Kharasch VS et al, Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and, cyclophosphamide in osteosarcoma survivors, Med Pediatr Oncol. 1996 Aug;27(2):85-91Kharasch VS et al, Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and, cyclophosphamide in osteosarcoma survivors, Med Pediatr Oncol. 1996 Aug;27(2):85-91
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22820
    Study title: Ben Arush MW et al, Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer, Pediatr Hematol Oncol. 1997 Jul-Aug;14(4):381-6Ben Arush MW et al, Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer, Pediatr Hematol Oncol. 1997 Jul-Aug;14(4):381-6
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22818
    Study title: Hamilton VM et al, Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease, J Pediatr Hematol Oncol. 2001 Feb;23(2):84-8Hamilton VM et al, Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease, J Pediatr Hematol Oncol. 2001 Feb;23(2):84-8
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22782
    Study title: Arndt CA et al Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide Eur J Cancer. 1998 Jul;34(8):1224-9
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26793
    Study title: Arndt CA et al Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group Pediatr Blood Cancer 2008 Jan;50(1):33-6
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26674
    Study title: Kellie SJ et al, Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach, Pediatr Blood Cancer. 2004 Aug;43(2):126-33
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26867
    Study title: Marks DI et al, A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling, allografting for acute lymphoblastic leukemia in first or second complete, remission, Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26890
    Study title: Simon T et al, Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk, neuroblastoma. Results of a phase-II trial, J Cancer Res Clin Oncol. 2007 Sep;133(9):653-61. Epub 2007 May 4
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26926
    Study title: Spitzer TR et al Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children Int J Radiat Oncol Biol Phys 1994 Apr 30;29(1):39-44
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26752
    Study title: Spitzer TR et al, Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children, Int J Radiat Oncol Biol Phys 1994 Apr 30;29(1):39-44
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26806
    Study title: Méresse V et al, Combined continuous infusion etoposide with high-dose cyclophosphamide for, refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique, J Clin Oncol. 1993 Apr;11(4):630-7
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26952
    Study title: Milano GM et al High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.Cancer 2006 Apr 15;106(8):1838-45. Erratum in: Cancer 2006 Sep 15;107(6):1421
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26679
    Study title: Milano GM et al High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience Cancer. 2006 Apr 15;106(8):1838-45. Erratum in: Cancer. 2006 Sep 15;107(6):1421
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26779
    Study title: Arndt CA et al Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group Pediatr Blood Cancer. 2008 Jan;50(1):33-6
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26792
    Study title: Bacci G et al Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies Cancer 1998 Mar 15;82(6):1174-83
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26701
    Study title: Bacci G et al Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed afteradding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide,and doxorubicin in the maintenance phase--results of two sequential studies Cancer. 1998 Mar 15;82(6):1174-83
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26780
    Study title: Bacci G et al Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patientstreated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin,cyclophosphamide, dactinomycin, ifosfamide and etoposide) Minerva Pediatr. 1995 Nov;47(11):457-69. Italian
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26781
    Study title: Sandler ES et al, Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous, leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium, Med Pediatr Oncol. 2000 Oct;35(4):403-9
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26900
    Study title: Donfrancesco A et al, Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age, Acta Paediatr Suppl. 2004 May;93(445):6-11
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26935
    Study title: Duerst RE et al, Allogeneic bone marrow transplantation for children with acute leukemia:, cytoreduction with fractionated total body irradiation, high-dose etoposide and, cyclophosphamide, Bone Marrow Transplant. 2000 Mar;25(5):489-94
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26880
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:30:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA